Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Sources Sought opportunity from Department Of Health And Human Services was posted on April 19, 2021. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Centers for Research on Structural Biology of Infectious Diseases

Closed
HHS-SBSS-75N93021R00009Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 25 days
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

5 days ago

DEADLINE

in 3 days

General Info

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

MD

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more
Introduction This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. Background The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS) supports research related to the basic understanding, treatment and ultimately prevention of infectious, immune-mediated and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports a comprehensive extramural research program focused on the prevention and control of diseases caused by virtually all infectious agents (with the exception of the Human Immunodeficiency Virus (HIV)). The NIAID is re-competing the Structural Genomics Centers for Infectious Diseases (SGCID) program, herein now referred to as the Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID). In 2007, the NIAID established two five-year contracts to support the SGCID program. These SGCID centers focused on determining three-dimensional (3D) structures of protein targets of biomedical interest. The SGCID program was re-competed in 2012 and two five-year contracts were awarded to the incumbents. In 2017, the SGCID program was again recompeted and two five-year contracts were awarded to the incumbents (https://www.niaid.nih.gov/research/structural-genomics-centers-infectious-diseases-resources): 1. Seattle Biomedical Research Institute (novated to Seattle Children's Research Institute) (Contract No. HHSN272201700059C) 2. Northwestern University (Contract No. HHSN272201700060C) Purpose and Objectives The goal of the CRSTAL-ID program is to continue to support experimental determination of 3D protein structures and other molecules with important biological roles across human pathogens, and pathogen and host proteins involved in host-pathogen interactions. Pathogens include those on the NIAID Category A-C Priority Pathogen lists and organisms associated with emerging and re-emerging infectious diseases: https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens. This CRSTAL-ID program will support research projects that utilize experimental approaches to define the molecular mechanisms of protein targets and gain further insight into the functional roles of these targets. Knowledge from these protein structures and their molecular functions will inform: 1) a structural view of biological processes and pathways which will assist systems-level investigations; and 2) insights into functional mechanisms of the protein target(s), either in complex with other biological molecules or with synthetic compounds. Moreover, the CRSTAL-ID program will support projects that perform structure-guided vaccine design and drug discovery and will conduct evaluation and validation assays required for therapeutic use against infectious diseases. This rational structure-guided approach will improve selectivity, specificity and optimization of drug and vaccine development pipelines. Of critical importance, the CRSTAL-ID program will support projects on antimicrobial resistance and pandemic preparedness for emerging infectious disease threats with a focus on viruses with epidemic or pandemic potential to aid in coordination of NIAID response efforts. The 3D structure information, reagents and services provided by the CRSTAL-ID centers will be made freely available to the broad scientific community. Project requirements The purpose of this anticipated solicitation is for scientific support of the CRSTAL-ID program through a) generation of 3D structures for targets derived from bacterial, viral, eukaryotic and other human pathogens using state-of-the-art high-throughput (HTP) technologies and structural biology methodologies including x-ray crystallography, Nuclear Magnetic Resonance (NMR), Cryo-Electron Microscopy (cryo-EM), and structural modeling; b) characterization of molecular functions and biochemical properties of selected targets; c) evaluation of structure-guided design and functional studies of drug targets and vaccine candidates; d) provision of pandemic preparedness and rapid response to emerging infectious diseases threats and programmatic priorities; e) provision of a 3D structure determination service to the external scientific community; and f) dissemination of contract generated resources, including all 3D structure information and reagents. Anticipated period of performance It is anticipated that two (2) cost reimbursement, level of effort type contracts will be awarded with a one-year base period of performance beginning on or around June 1, 2022. Awards are expected to include 4 one-year option periods. The Government's base level of effort requirement is estimated at 31,200 labor hours for each contract year, equating to 15 FTE's with an FTE being defined as 2,080 hours. In addition to the base level of effort, each year of performance is anticipated to contain an option quantity for up to 12 additional FTEs. Capability statement / information sought Sources are expected to have the expertise, personnel, and facilities to meet requirements of this project. Tailored Capability Statements submitted as a result of this announcement should demonstrate the offerors qualifications and experience, specifically providing evidence as to their capability to perform this requirement, with particular attention to the following technical areas: The ability to establish and maintain a CRSTAL-ID program that applies state-of-the art HTP technologies and structural biology methodologies to experimentally characterize the 3D atomic structure of proteins or other molecules having an important biological role belonging to human pathogens, include those in the NIAID Category A-C Priority Pathogen lists and organisms causing emerging and re-emerging infectious diseases https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens The ability to establish and implement projects aimed at characterizing the molecular functional role and biochemical properties of targets whose 3D structure was determined by the incumbent NIAID SGCID centers. The ability to establish and implement projects aimed at performing structure-guided vaccine design and drug discovery, and evaluation and validation of the underlying mechanism of action required for therapeutic use against infectious diseases. The ability to establish and implement projects aimed at performing pandemic preparedness for emerging infectious disease threats with a focus on viruses with epidemic or pandemic potential to aid in the NIAID pandemic preparedness and response strategy and facilitate rapid response measures. The ability to establish data management system, computational infrastructure and bioinformatics capability to support data management and analysis, algorithm and software application development, and other computational approaches for assisting target selection and in silico screening for structure-guided vaccine design and drug discovery. The ability to provide structure determination services to the external scientific community and to establish processes to engage external investigators for collecting recommendations for targets for structure determination. The ability to ensure that all contract-generated resources are publicly available and easily accessible to the scientific community. The ability to establish a multi-disciplinary team with adequate scientific and technical personnel according to meet the required labor hours per contract year. The ability to provide a technical and administrative management infrastructure to ensure the efficient planning, implementation, oversight, and completion of all required activities. The ability to provide facilities, equipment, space, and other resources necessary to carry out the required activities. Page Limitations: Interested qualified small business organizations should submit a tailored Capability Statement not to exceed five pages, excluding resumes. Capability Statements must not include links to internet web site addresses (URLs) or otherwise direct readers to alternate sources of information. Font size must be 10 to 12 points. Spacing must be no more than 15 characters per inch. Within a vertical inch, there must be no more than six lines of text. Print margins must be at least one-inch on each edge of the paper. Print setup should be single-sided on standard letter size paper (8.5 x 11" in the U.S., A4 in Europe). All proprietary information should be marked as such. Required Business Information: DUNS. Company Name. Company Address. Company Point of Contact, Phone and Email address Current GSA Schedules and/or Government-wide Acquisition Contracts (GWACs) appropriate to this Sources Sought. Do you have a Government approved accounting system? If so, please identify the agency that approved the system. Type of Company (i.e., small business, 8(a), woman owned, veteran owned, etc.) as validated via the System for Award Management (SAM) located at https://www.sam.gov/index.html/#1. This indication should be clearly marked on the first page of your Capability Statement (preferable placed under the eligible small business concern's name and address). Number of Copies: Please submit one (1) electronic copy of your response as follows: All Capability Statements sent in response to this Small Business Sources Sought notice must be submitted electronically (via e-mail) to Swee Teo, Contracting Officer, at teosl@niaid.nih.gov in MS Word or Adobe Portable Document Format (PDF). The e-mail subject line must specify HHS-SBSS-75N93021R00009. Facsimile responses will not be accepted. Common Cut-off Date: Electronically submitted tailored capability statements are due no later than 3:00PM (Eastern Prevailing Time) on May 5, 2021. CAPABILITY STATEMENTS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Beta.SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS